Company
Evgen Pharma plc
Headquarters: Wilmslow, United Kingdom
Employees: 8
CEO: Dr. Huw Jones BSc, Ph.D.
Market Cap
£3.4 Million
GBP as of Jan. 1, 2025
US$4.3 Million
Evgen Pharma plc Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections. Evgen Pharma plc was founded in 2007 and is headquartered in Nether Alderley, the United Kingdom.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Evgen Pharma plc has the following listings and related stock indices.
Stock: LSE: EVG wb_incandescent